Increased drug resistance in breast cancer by tumor-associated macrophages through IL-10/STAT3/bcl-2 signaling pathway

Medical Oncology

Volumn 32, Issue 2, 2015, Pages

  Yang, Cuixia ^a   He, Linyan ^a,b   He, Pingqing ^a   Liu, Yiwen ^a   Wang, Wenjuan ^a   He, Yiqing ^a   Du, Yan ^a   Gao, Feng ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Breast cancer; Chemoresistance; Tumor associated macrophages

Indexed keywords

CELL SURFACE MARKER; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; MESSENGER RNA; NEUTRALIZING ANTIBODY; PACLITAXEL; PROTEIN BCL 2; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; IL10 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; DRUG CYTOTOXICITY; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; UPREGULATION; BREAST TUMOR; DRUG RESISTANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; MACROPHAGE; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INTERLEUKIN-10; MACROPHAGES; PROTO-ONCOGENE PROTEINS C-BCL-2; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84920854543     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0352-6     Document Type: Article

References (25)

1. Mellor AL, Munn DH. Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat Rev Immunol. 2008;8:74–80.
2. Solinas G, Germano G, Mantovani A, et al. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol. 2009;86:1065–73.
3. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002;196:254–65.
4. Ojalvo LS, King W, Cox D, et al. High-density gene expression analysis of tumor-associated macrophages from mouse mammary tumors. Am J Pathol. 2009;174:1048–64.
5. Mukhtar RA, Nseyo O, Campbell MJ, et al. Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics. Expert Rev Mol Diagn. 2011;11:91–100.
6. De Palma M, Lewis CE. Macrophages limit chemotherapy. Nature. 2011;472:303–4.
7. Mantovani A, Sica A, Allavena P, et al. Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum Immunol. 2009;70:325–30.
8. McMillin DW, Delmore J, Weisberg E, et al. Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med. 2010;16:483–9.
9. Jinushi M, Chiba S, Yoshiyama H, et al. Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells. Proc Natl Acad Sci USA. 2011;108:12425–30.
10. Shree T, Olson OC, Elie BT, et al. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev. 2011;25:2465–79.
11. Sica A, Schioppa T, Mantovani A, et al. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer. 2006;42:717–27.
12. Moore KW, O’garra A, Malefyt RW, et al. Interleukin-10. Annu Rev Immunol. 1993;11:165–90.
13. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–7.
14. Gritsko T, Williams A, Turkson J, et al. Persistent activation of STAT3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res. 2006;12:11–9.
15. Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin’s lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res. 2001;61:5137–44.
16. Sun Z, Yao Z, Liu S, et al. An oligonucleotide decoy for STAT3 activates the immune response of macrophages to breast cancer. Immunobiology. 2006;211:199–209.
17. Cohen SBA, Crawley JB, Kahan MC, et al. Interleukin-10 rescues T cells from apoptotic cell death: association with an upregulation of Bcl-2. Immunology. 1997;92:1–5.
18. Duan Z, Foster R, Bell DA, et al. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res. 2006;12:5055–63.
19. Müllauer L, Gruber P, Sebinger D, et al. Mutations in apoptosis genes: a pathogenetic factor for human disease. Mutat Res/Rev Mutat Res. 2001;488:211–31.
20. Mantovani A, Schioppa T, Porta C, et al. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev. 2006;25:315–22.
21. Tjiu JW, Chen JS, Shun CT, et al. Tumor-associated macrophage-induced invasion and angiogenesis of human basal cell carcinoma cells by cyclooxygenase-2 induction. J Invest Dermatol. 2008;129:1016–25.
22. Yang C, Cao M, Liu H, et al. The high and low molecular weight forms of hyaluronan have distinct effects on CD44 clustering. J Biol Chem. 2012;287:43094–107.
23. Moore KW, de Waal Malefyt R, Coffman RL, et al. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;9:683–765.
24. Vega MI, Huerta-Yepaz S, Garban H, et al. Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance. Oncogene. 2004;23:3530–40.
25. Komohara Y, Horlad H, Ohnishi K, et al. Importance of direct macrophage–tumor cell interaction on progression of human glioma. Cancer Sci. 2012;103:2165–72.